文献速递淋巴瘤

帕博利珠单抗联合利妥昔单抗治疗复发或难治性滤泡性淋巴瘤的安全性与活性

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma.
PubMed 文献 · Blood Adv · 2022-01-01

单中心、开放标签、2期试验纳入30例既往≥1线治疗后复发、对利妥昔单抗敏感的滤泡性淋巴瘤患者,接受帕博利珠单抗200 mg IV每3周最多16周期联合利妥昔单抗375 mg/m2 IV第1周期每周4周。总缓解率67%,完全缓解率50%,中位无进展生存期12.6个月(95%CI 8.2-27.6),中位随访35个月时23%患者仍缓解。

要点

  • 总缓解率67%,完全缓解率50%,中位无进展生存期12.6个月(95%CI 8.2-27.6)。
  • 3/4级不良事件包括肝酶异常、腹泻、恶心、无菌性脑膜炎、胰腺炎,各3%。
  • 低级别免疫相关不良事件80%,3/4级免疫相关不良事件13%,20%因治疗相关不良事件停药。

核心结论

  • 在单臂2期研究中,帕博利珠单抗联合利妥昔单抗在复发滤泡性淋巴瘤中显示出有利的疗效和安全性。

研究设计与样本

  • 单中心、开放标签、2期试验,纳入30例既往≥1线治疗后复发、对利妥昔单抗敏感的滤泡性淋巴瘤患者。
  • 帕博利珠单抗200 mg IV每3周最多16周期;利妥昔单抗375 mg/m2 IV仅在第1周期每周给药共4周。
  • 试验注册号NCT02446457。

主要发现

  • 最常见3/4级不良事件为肝酶异常(3%)、腹泻(3%)、恶心(3%)、无菌性脑膜炎(3%)和胰腺炎(3%)。
  • 低级别免疫相关不良事件见于80%患者,包括腹泻(43%)、肝酶异常(33%)、甲状腺功能障碍(27%)和皮疹(23%)。
  • 3或4级免疫相关不良事件发生于13%患者,治疗相关不良事件导致6例(20%)患者停药。
  • 总缓解率(主要终点)67%,完全缓解率50%;中位无进展生存期12.6个月(95%CI 8.2-27.6),3年总生存率97%,中位随访35个月时23%患者处于缓解。
  • 基线肿瘤高CD8+ T效应评分与完全缓解诱导及无进展生存期改善相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PD-1 blockade enhances the function of antitumor T cells and antibody-dependent, cell-mediated cytotoxicity (ADCC) of NK cells. In a single-center, open-label, phase 2 trial, we tested the combination of pembrolizumab, an anti-PD-1 monoclonal antibody, and rituximab, an anti-CD20 monoclonal antibody that induces ADCC, in 30 patients with follicular lymphoma (FL) with rituximab-sensitive disease who had relapsed after ≥1 prior therapy. Pembrolizumab was administered at 200 mg IV every 3 weeks for up to 16 cycles, and rituximab was given at 375 mg/m2 IV weekly for 4 weeks in cycle 1 only. The most common grade 3/4 adverse events (AEs) were liver enzyme abnormalities (3%), diarrhea (3%), nausea (3%), aseptic meningitis (3%), and pancreatitis (3%). Low-grade immune-related AEs were reported in 80% of patients, including diarrhea (43%), liver enzyme abnormalities (33%), thyroid dysfunction (27%), and rash (23%). Grade 3 or 4 immune-related AEs occurred in 13% of the patients. Treatment-related AEs led to discontinuation in 6 (20%) patients. The overall response rate (primary end point) was 67%, and the complete response (CR) rate was 50%. Median progression-free survival (PFS) was 12.6 months (95% confidence interval, 8.2-27.6), the 3-year overall survival rate was 97%, and 23% of patients were in remission at a median follow-up of 35 months. The presence of a high CD8+ T-effector score at baseline in the tumor was associated with induction of a CR and improved PFS. In this single-arm, phase 2 study, the combination of pembrolizumab and rituximab demonstrates favorable efficacy and safety profile in relapsed FL. This trial is registered at www.clinicaltrials.gov as #NCT02446457.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nastoupil LJ, Chin CK, Westin JR, et al. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv. 2022. PMID: 35015819. doi:10.1182/bloodadvances.2021006240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。